Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note.

Longitudinal studies of cognitive function in Alzheimer's disease (AD) patients are powerful tools to better understand the biology and natural history of the disease, but the attributes of the studies that make them valuable also pose special challenges to analysts. A fundamental problem is the accurate measure of time at which cognitive decline begins. Investigators typically use the date of AD diagnosis or the date of enrollment in an AD study. If the rate of cognitive decline is non-linear, variables associated with the time of diagnosis or enrollment might artificially be associated with the rate of decline. Unlike the mixed effects models typically used to analyse cognitive decline, summary measure analyses do not directly compare the rate of decline with time since decline began, and, therefore, are less sensitive to biased measures of time of decline. We simulated trajectories of cognitive decline using the multivariate normal random effect model and tested the ability of the two analytic techniques to discriminate between true and spurious associations. Our analyses suggest summary measure models are less likely to detect spurious associations generated by biased measures of time at which decline begins, and more likely to detect true associations concealed by biased time measurement.

[1]  A. Kurz,et al.  Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease , 1996, Neurology.

[2]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[3]  T J Rosen,et al.  Age at Onset and Rate of Progression of Alzheimer's Disease , 1987, Journal of the American Geriatrics Society.

[4]  B. Winblad,et al.  Apolipoprotein ϵ4 allele and disease progression in patients with late-onset Alzheimer's disease , 1995, Neuroscience Letters.

[5]  J. Hughes,et al.  Cognitive deterioration in Alzheimer's disease: behavioral and health factors. , 1990, Journal of gerontology.

[6]  Nan M. Laird,et al.  Using the General Linear Mixed Model to Analyse Unbalanced Repeated Measures and Longitudinal Data , 1997 .

[7]  B T Hyman,et al.  Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.

[8]  E B Larson,et al.  Head Circumference as a Measure of Cognitive Reserve , 1996, British Journal of Psychiatry.

[9]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[10]  R. Brookmeyer,et al.  Apolipoprotein E genotype and rate of decline in probabole Alzheimer's disease , 1996 .

[11]  Yaakov Stern,et al.  The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease , 1997, Annals of neurology.

[12]  N. Cook,et al.  Design and analysis methods for longitudinal research. , 1983, Annual review of public health.

[13]  R. Brookmeyer,et al.  Predicting Rate of Cognitive Decline in Probable Alzheimer's Disease , 1996, Brain and Cognition.

[14]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[15]  Y. Stern,et al.  Preliminary Findings from the Predictors Study: Utility of Clinical Signs for Predicting Disease Course , 1995, Alzheimer disease and associated disorders.

[16]  P. Tiraboschi,et al.  Rate of Progression and Prognostic Factors in Alzheimer's Disease: A Prospective Study , 1993, Journal of the American Geriatrics Society.

[17]  E B Larson,et al.  Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  J. Becker,et al.  Predictors of Decline in Alzheimer's Disease , 1991, Cortex.

[19]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[20]  K. Davis,et al.  Deterioration on the blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes , 1992, Psychiatry Research.

[21]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[22]  R B Wallace,et al.  Longitudinal application of cognitive function measures in a defined population of community-dwelling elders. , 1991, Annals of epidemiology.

[23]  S. Corkin,et al.  Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.

[24]  Anthony F Jorm,et al.  Controlled and automatic information processing in senile dementia: a review , 1986, Psychological Medicine.

[25]  E. Corder,et al.  Apolipoprotein E Genotype and Rate of Decline in Probable Alzheimer's Disease , 1996 .

[26]  K. Blennow,et al.  Heterogeneity of the Course of Alzheimer's Disease: A Differentiation of Subgroups , 1991 .

[27]  B. O’Donnell,et al.  The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course. , 1990, Archives of neurology.

[28]  M. Rossor,et al.  Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. , 1995, American journal of medical genetics.

[29]  M. Finch,et al.  Predictors of cognitive and functional progression in patients with probable Alzheimer's disease , 1992, Neurology.

[30]  J. Yesavage,et al.  No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. , 1997, The American journal of psychiatry.